SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

TYPE OF INFORMATION SEARCH RESULT

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

PETROLEUM GEO-SERVICES

puce PGS Optimizing Vessel Speed - HTML (w)

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

Essilor Luxottica

puce EssilorLuxottica : EssilorLuxottica and Coach renew global license agreement - HTML (w)

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

Essilor Luxottica

puce EssilorLuxottica : EssilorLuxottica et Coach renouvellent leur accord de licence mondial - HTML (w)

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

Italian version HTML (w) Mail

Essilor Luxottica

puce EssilorLuxottica : EssilorLuxottica e Coach rinnovano l’accordo di licenza - HTML (w)

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children - HTML (w)

2021.06.25 | 07:30 | Permanent Information Releases / Notification of availability

French version HTML (w) Mail

Sanofi-Aventis

puce Sanofi : Mise en ligne du document «Q2 2021 Memorandum for modelling purposes» - HTML (w)

2021.06.25 | 07:30 | Permanent Information Releases / Notification of availability

English version HTML (w) Mail

Sanofi-Aventis

puce Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes - HTML (w)

2021.06.25 | 07:15 | Permanent Information Releases / General Company News

French version HTML (w) Mail

Sanofi-Aventis

puce Sanofi : La Commission européenne approuve Libtayo® (cemiplimab), premier médicament d’immunothérapie indiqué pour le traitement du carcinome basocellulaire au stade avancé - HTML (w)

2021.06.25 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

Sanofi-Aventis

puce Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma - HTML (w)

2021.06.25 | 07:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

Sanofi-Aventis

puce Sanofi : La Commission européenne approuve Libtayo® (cemiplimab) pour le traitement de première ligne du cancer du poumon non à petites cellules exprimant =50 % de cellules tumorales PD-L1 positives - HTML (w)

2021.06.25 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

Sanofi-Aventis

puce Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with =50% PD-L1 expression - HTML (w)

2021.06.24 | 22:30 | / Notes and Bonds

French version HTML (w) Mail

Air France-KLM

puce Air France-KLM place avec succès une émission obligataire de 800 millions d’euros en deux tranches - HTML (w)

2021.06.24 | 22:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

Air France-KLM

puce Success of Air France-KLM’s €800 million notes issue via two tranches - HTML (w)

2021.06.24 | 20:33 | Permanent Information Releases / General Company News

English version HTML (w) Mail

Vallourec

puce VALLOUREC ANNOUNCES THE SUCCESS OF ITS RIGHTS ISSUE FOR C. €300 MILLION WITH SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS - HTML (w)

2021.06.24 | 20:30 | Permanent Information Releases / General Company News

French version HTML (w) Mail

Vallourec

puce VALLOUREC ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION D’ENVIRON 300 MILLIONS D’EUROS - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000